These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019 [TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners. Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331 [TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R. Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132 [TBL] [Abstract][Full Text] [Related]
5. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423 [TBL] [Abstract][Full Text] [Related]
6. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase. Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904 [TBL] [Abstract][Full Text] [Related]
7. Specificity of alpha-cyano-beta-hydroxy-beta-methyl-n-[4-(trifluoromethoxy)phe nyl]-propenamide as an inhibitor of the epidermal growth factor receptor tyrosine kinase. Ghosh S; Zheng Y; Jun X; Mahajan S; Mao C; Sudbeck EA; Uckun FM Clin Cancer Res; 1999 Dec; 5(12):4264-72. PubMed ID: 10632369 [TBL] [Abstract][Full Text] [Related]
8. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415 [TBL] [Abstract][Full Text] [Related]
9. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines. Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527 [TBL] [Abstract][Full Text] [Related]
10. Sporostatin, a novel and specific inhibitor of EGF receptor kinase. Murakami Y; Ishii A; Mizuno S; Yaginuma S; Uehara Y Anticancer Res; 1999; 19(5B):4145-9. PubMed ID: 10628366 [TBL] [Abstract][Full Text] [Related]
11. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Huang Y; Li X; Jiang J; Frank SJ Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991 [TBL] [Abstract][Full Text] [Related]
12. Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase. Takeuchi K; Shin-ya T; Nishio K; Ito F FEBS J; 2009 Mar; 276(5):1255-65. PubMed ID: 19175673 [TBL] [Abstract][Full Text] [Related]
13. Daphnetin, one of coumarin derivatives, is a protein kinase inhibitor. Yang EB; Zhao YN; Zhang K; Mack P Biochem Biophys Res Commun; 1999 Jul; 260(3):682-5. PubMed ID: 10403826 [TBL] [Abstract][Full Text] [Related]
14. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma. Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130 [TBL] [Abstract][Full Text] [Related]
15. 4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity. Buchdunger E; Mett H; Trinks U; Regenass U; Müller M; Meyer T; Beilstein P; Wirz B; Schneider P; Traxler P Clin Cancer Res; 1995 Aug; 1(8):813-21. PubMed ID: 9816050 [TBL] [Abstract][Full Text] [Related]
16. Activation mechanism of solubilized epidermal growth factor receptor tyrosine kinase. Ge G; Wu J; Wang Y; Lin Q Biochem Biophys Res Commun; 2002 Jan; 290(3):914-20. PubMed ID: 11798160 [TBL] [Abstract][Full Text] [Related]
18. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers. Maegawa M; Takeuchi K; Funakoshi E; Kawasaki K; Nishio K; Shimizu N; Ito F Mol Cancer Res; 2007 Apr; 5(4):393-401. PubMed ID: 17426253 [TBL] [Abstract][Full Text] [Related]
19. Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways. Huang L; Watanabe M; Chikamori M; Kido Y; Yamamoto T; Shibuya M; Gotoh N; Tsuchida N Oncogene; 2006 Oct; 25(49):6457-66. PubMed ID: 16702953 [TBL] [Abstract][Full Text] [Related]
20. Activation of calcium-dependent kinases and epidermal growth factor receptor regulate muscarinic acetylcholine receptor-mediated MAPK/ERK activation in thyroid epithelial cells. Montiel M; Quesada J; Jiménez E Cell Signal; 2007 Oct; 19(10):2138-46. PubMed ID: 17643958 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]